6Cohen AT, Agnelli G, Anderson FA, et al.Venous thromboembo- lism (~TE) in Europe. The number of YTE events and associated morbidity and mortality [J].Thromb Haemost, 2007, 98(4): 756-764.
7Kahn SR, Shrier I, Julian JA, et al.Detemfinants and time course of the postthrombotic syndrome after acute deep venous throm- bosis [J ] .Ann Intern Med,2008,149(10): 698-707.
8Kearon C, Akl EA, Cemerota AJ, et aLAntithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed : American College of Chest Physicians Evi- dence-Based Clinical Practice Guidelines [J].Chest,2012, 141 (suppl) : 419-494.
9Howard LS, Hughes RJ.NICE guideline : management of venous thromboembolic diseases and role of thrombophilia testing [J]. Thorax,2013, 68 : 391-393.
10Perzborn E, Roehrig S, Straub A, et al. Rivaroxaban: a new oral factor Xa inhibitor [J].Arterioscler Thromb Vasc Biol,2010, 30: 376-381.
